President / CEO

R. Harrison

CompanyName

04

List item

Here is something else that will be happening at this event!

FOUNDER

RODRIGO GUTIERREZ

Corialent

12 years ago, Rodrigo decided that the Coca Colas of the world shouldn’t be the only ones who get to have all the fun in the advertising industry. He was sick of all the dull, corporate, navy blue and white B2B work out there. Business people are people too. Corialent specializes in B2B marketing that doesn’t suck. And they want to get the rest of the industry drinking that delicious KoolAid.

Corialent Now Conference
Sat
, 
November 
23 
10:00am
Ticket Sales Are Closed
Text goes here
X

FOUNDER

RODRIGO GUTIERREZ

Corialent

12 years ago, Rodrigo decided that the Coca Colas of the world shouldn’t be the only ones who get to have all the fun in the advertising industry. He was sick of all the dull, corporate, navy blue and white B2B work out there. Business people are people too. Corialent specializes in B2B marketing that doesn’t suck. And they want to get the rest of the industry drinking that delicious KoolAid.

FOUNDER

RODRIGO GUTIERREZ

Corialent

12 years ago, Rodrigo decided that the Coca Colas of the world shouldn’t be the only ones who get to have all the fun in the advertising industry. He was sick of all the dull, corporate, navy blue and white B2B work out there. Business people are people too. Corialent specializes in B2B marketing that doesn’t suck. And they want to get the rest of the industry drinking that delicious KoolAid.

FOUNDER

RODRIGO GUTIERREZ

Corialent

12 years ago, Rodrigo decided that the Coca Colas of the world shouldn’t be the only ones who get to have all the fun in the advertising industry. He was sick of all the dull, corporate, navy blue and white B2B work out there. Business people are people too. Corialent specializes in B2B marketing that doesn’t suck. And they want to get the rest of the industry drinking that delicious KoolAid.

FOUNDER

RODRIGO GUTIERREZ

Corialent

12 years ago, Rodrigo decided that the Coca Colas of the world shouldn’t be the only ones who get to have all the fun in the advertising industry. He was sick of all the dull, corporate, navy blue and white B2B work out there. Business people are people too. Corialent specializes in B2B marketing that doesn’t suck. And they want to get the rest of the industry drinking that delicious KoolAid.

FOUNDER

RODRIGO GUTIERREZ

Corialent

12 years ago, Rodrigo decided that the Coca Colas of the world shouldn’t be the only ones who get to have all the fun in the advertising industry. He was sick of all the dull, corporate, navy blue and white B2B work out there. Business people are people too. Corialent specializes in B2B marketing that doesn’t suck. And they want to get the rest of the industry drinking that delicious KoolAid.

2:00PM

Event

Enter the event description here.

The Event
Speakers
Attendees
Schedule
The Final Countdown!
Time left for the event days hours minutes seconds
The countdown doesn't work if the event start date is set to TBD
1st Alcor New York Symposium

Cryonics returns to its New York roots on November 23 when we organize our first Alcor New York Symposium.

Tickets
Text goes here
X


Dr. Emil  Kendziorra

President of the Board of the European Biostasis Foundation

Dr. Emil Kendziorra is the President of the Board of the non-profit European Biostasis Foundation based in Switzerland. He has a strong background in medicine, cancer research and entrepreneurship. He has been CEO of multiple tech and medical companies, most recently as a Founder and CEO of Medlanes, the dominant digital house call provider in Germany. Before that he ran companies from digital agencies to data analysis companies. Emil graduated summa cum laude in medicine from University Medical Center Göttingen - one of the leading medical schools in Germany - with a doctoral degree in translational cancer research. He’s a regular keynote speaker on future of healthcare policy, the overlap of healthcare, science and technology as well as an advisor to insurances, hospital chains and pharmaceutical companies on digitalization topics.


Dr. Robin Hanson

Associate professor of economics at George Mason University & Research Associate at the Future of Humanity Institute of Oxford University

Dr. Hanson has a doctorate in social science from California Institute of Technology, master's degrees in physics and philosophy from the University of Chicago, and nine years experience as a research programmer, at Lockheed and NASA.

Oxford University Press published his book The Age of Em: Work, Love and Life When Robots Rule the Earth in June 2016, and his book The Elephant in the Brain: Hidden Motives in Everyday Life, co-authored with Kevin Simler, in January, 2018.

Professor Hanson has pioneered prediction markets, also known as information markets and idea futures, since 1988. He was a principal architect of the first internal corporate markets, at Xanadu in 1990, of the first web markets, the Foresight Exchange since 1994, of DARPA's Policy Analysis Market, from 2001 to 2003, and of IARPA's combinatorial markets DAGGRE and SCICAST from 2010 to 2015. He has written and spoken widely on the application of idea futures to business and policy, and has advised many ventures. He suggests "futarchy", a form of governance based on prediction markets.


Ben Best

NAD+ Restoration and Senolytic Therapy

Ben Best has subjected himself to two age reversal therapies: (1) senolytic therapy (therapy to eliminate senescent cells using dasatinib and quercetin) and (2) NAD+ infusions (to restore NAD+ to youthful levels). He has also attended several conferences dealing with these subjects as well as studied and written about them, the results of which he will provide in his presentation.


Aschwin de Wolf

Co-founder and CEO of Advanced Neural Biosciences.

Aschwin de Wolf is the co-founder and CEO of Advanced Neural Biosciences. He worked in cryonics since 2004. At Suspended Animation (2004-2007) he was involved in readiness planning, creating standby and cryoprotection capabilities, and writing protocols and documentation. In 2008 he created Advanced Neural Biosciences with Chana Phaedra to research cryopreservation of the brain and the effects of ischemia on cryopreservation. He is also the editor of Alcor’s Cryonics magazine and co-author of Alcor’s comprehensive technical procedures manual. At Advanced Neural Biosciences he splits his time between designing most of its research and experiments and strategic long-term planning, communications, and fund raising.


Dr. Roman Bauer

Research fellow and Head of an Interdisciplinary lab at Newcastle University (UK)

Dr. Bauer studied Computational Science and Engineering at ETH Zürich, where he afterwards did his doctoral studies in Computational Neuroscience. He has co-authored over 20 publications in computational biology including multiple medically relevant topics, and he leads the BioDynaMo collaboration (https://biodynamo.web.cern.ch/) for the modelling and simulation of biological tissue dynamics. Dr. Bauer is also a member of the UK Cryonics and Cryopreservation Research Network and of the European Biostasis Foundation Advisory Board. His current research focuses on the computational modelling of cryopreservation, in particular neural tissue cryopreservation. 


Dr. Regina R. Monaco

Research Fellow at Ronin Institute

Regina R. Monaco, Ph.D. is a Neuroscience Research Fellow at the Ronin Institute where she studies properties of biological neural networks using machine learning and thermodynamic (entropic) measures to aid in deconvolution of raw data (EEG, fMRI, spike-trains) generated from mammalian connectomes to discover system-wide functional correlations. She also studies computational dynamic models of small neural networks and the emergent characteristic properties and patterns of these networks.

She has worked as a Senior Researcher, Fellow, or Adjunct Assistant Professor at a number of universities over her career, including University of Texas San Antonio, NYU, Syracuse University, University of Illinois Urbana,  Columbia University, NASA Ames, and most recently, Mount Sinai Health System. Her research utilizes theoretical computational methods to define dynamic and mechanistic interactions of macromolecular complexes, including drug/DNA complexes, DNA repair complexes including THIIH,  structure and activity of the XPD subunit, properties of porphyrins covalently tethered to DNA octamers, 3D structural predictions of small RNA prebiotic polymers, genetic replication fidelity, and luminescent biomolecules, such as GFP-related molecules. She also studies smaller biological molecules including bacteriorhodopsin (MD simulations), ras-p21, EFGR, G-binding proteins, phytoene synthase (PSY-1), GNRH, and rap-1a. She worked on a bioinformatic study of pharmaceutical agents to find off-label uses by determining which receptors these molecules bind to..


Dr. Ralf Spindler


Dr. Spindler received a Diplom-Ingenieur in electrical engineering from Karlsruhe Institute of Technology and a Master of Science in Biomedical Engineering from RWTH Aachen University. He completed a Doktor-Ingenieur from Leibniz Universität Hannover in the field of cryopreservation (accredited as Ph.D. by Foreign Credential Evaluations, www.ece.org). He has co-authored over 20 publications in this area. He is an inventor and has also work experience in medical device design and neuroscience.


Dr. João Pedro de Magalhães

Institute of Ageing and Chronic Disease, University of Liverpool

     Dr de Magalhaes graduated in Microbiology in 1999 from the Escola Superior de Biotecnologia in his hometown of Porto, Portugal, and then obtained his PhD in 2004 from the University of Namur in Belgium. Following a postdoc at Harvard Medical School, in 2008 Dr de Magalhaes was recruited to the University of Liverpool. He is now an Associate Professor and leads the Integrative Genomics of Ageing Group (http://pcwww.liv.ac.uk/~aging/). His lab studies the ageing process and how we can manipulate it to fend off age-related diseases and improve human health. Dr de Magalhaes also coordinates the UK Cryonics and Cryopreservation Research Network (http://www.cryonics-research.org.uk/).


Chana Phaedra

Co-founder of Advanced Neural Biosciences

Chana Phaedra is co-founder of Advanced Neural Biosciences. Chana received her M.S. in Cognition and Neuroscience from The University of Texas at Dallas in 2003. She worked as a Research Associate at Alcor Life Extension Foundation prior to starting ANB. At ANB, Chana has been instrumental to the development of initial perfusion technologies as well as the hippocampal slice model and the hypothermic resuscitation model. Currently, she acts as laboratory manager and still carries out experiments as needed.


Michael Benjamin

Research Associate at Advanced Neural Biosciences

Michael Benjamin is a Research Associate at Advanced Neural Biosciences, joining the company in April of 2019. He brings with him 20 years of experience in physics, engineering and mathematics having worked at places such as NASA Goddard Space Flight Center, Brookhaven National Labs and Lockheed Martin. He is currently working on a comprehensive meta-analysis of all Alcor patient cases, an endeavor whose goal is to develop, experimentally validate, and refine a quantitative cryopreservation evaluation methodology.


In addition, he is a member of and an Academy Ambassador for the New York Academy of Sciences, a member of the Society for Industrial and Applied Mathematics and the Association for the Advancement of Science, a leadership team member for the New York City Chapter of Singularity University, founder of the Global Scleroderma Initiative and team member in a study to define standards of approval for the FDA for Scleroderma related treatments.


Dr. Mike Perry

Alcor

Dr. Perry was hired by Alcor in 1989 following two years of volunteer work at the Foundation. Dr. Perry monitors Alcor’s dewars, provides facility surveillance during off-work hours, and performs writing tasks and computer programming. He has authored or contributed to the automated cooldown and perfusion modeling programs and has maintained the patient log books for many years. He is a regular contributor to Alcor newsletters. He has been a member of Alcor since 1984.

Prior to working at Alcor, Dr. Perry worked as a computer programmer—from 1968 until 1987. He graduated from the University of Chicago in 1969 with a B.S. in Mathematics. He received an M.S. in Computer Science from Colorado University in 1979 and a Ph.D. in Computer Science from the same institution in 1984.

Dr. Perry has authored two books: Toward Self-Optimization of Machine Intelligence (Ph.D. Thesis), Los Osos, CA: Dove Systems, 1984; and Forever for All: Moral Philosophy, Cryonics, and the Scientific Prospects for Immortality, Parkland, FL: Universal Publishers, 2000. Prior to his Alcor experience Dr. Perry authored or coauthored several journal papers and technical reports on computerized tomography, for applications ranging from medicine to solar physics.

FOUNDER

Dr. Roman Bauer

Computational Biology Methods for Tissue Cryopreservation

In contrast to most other biomedical fields, tissue cryopreservation has remained relatively untouched by computational techniques. State-of-the-art cryopreservation still predominantly relies on trial-and-error and large numbers of experiments for the determination of protocol parameters. Roman Bauer will review milestones in computational and mathematical work towards better cryopreservation protocols, and will discuss how he sees future automated cryopreservation technologies maximize post-thaw tissue quality.

COORDINATOR

SALLY

TENLEY

The Business Awards

Sally knows every little detail of the best B2B campaigns of the past decade. As the coordinator of the industry’s biggest awards show, she knows the ins and outs of the most insightful strategies and inventive ideas in the space. Most important, she knows what all winners have in common: guts.


Ben Best

NAD+ Restoration and Senolytic Therapy

Ben Best has subjected himself to two age reversal therapies: (1) senolytic therapy (therapy to eliminate senescent cells using dasatinib and quercetin) and (2) NAD+ infusions (to restore NAD+ to youthful levels). He has also attended several conferences dealing with these subjects as well as studied and written about them, the results of which he will provide in his presentation.

DETAILS

DATE

DATE

September 
28 
2019 
7:00am 
11:00pm

LOCATION

TIME

Saturday 
7:00am 
11:00pm
The Final Countdown!
Time left for the event days hours minutes seconds
The countdown doesn't work if the event start date is set to TBD

LOCATION

WHO SHOULD ATTEND

Anyone interested in Cryonics and Life Extension

#AlcorNewYork

Sharing is caring.

WHAT TO EXPECT

01

best practices

Learn best practices, strategies and ideas you can implement today.

02

GAIN INSIGHT

Hear from from some of the most innovative B2B marketers and technologists in the biz.

03

INSPIRATION

Leave inspired, invigorated and empowered.

Schedule


9:30AM

Sign In


10:00AM

Opening Remarks and Introduction to Cryonics

Aschwin de Wolf | CEO, Advanced Neural Biosciences

10:30AM

Dr. Pedro Magalhaes

Will We Cure Aging in My Lifetime?

 
People have always sought eternal life and everlasting youth. Recent technological breakthroughs, and our growing understanding of ageing, have given strength to the idea that a cure for human ageing can eventually be developed. Hundreds of genes are now known to regulate ageing in model organisms and can increase longevity by up to 10 fold and retard the process of ageing as a whole in animals. In addition, a large number of potential longevity-extending drugs already exist. Studies of species with exceptional longevity or disease resistance, like naked mole rats that are resistant to cancer or bowhead whales

that live over 200 years, may also help treat and prevent human diseases. Here, I will discuss recent advances in longevity science and human applications on the horizon. The scientific prospects of eradicating human ageing within the foreseeable future will also be discussed.

 

11:10AM

Dr. Regina R. Monaco

Low-Dose Pharmacological Interventions to Facilitate Healthy Aging – Reduction of Cancer Risk

 
In this talk I present and discuss several low dose pharmacological interventions which have been shown to have strong anti-cancer properties, as well as some other benefits such as reduction of chronic inflammation. I will review the mechanisms and anti-cancer benefits of low-dose therapy of the pharmaceuticals metformin, naltrexone, aspirin, and for women, tamoxifen (breast cancer). I will also discuss benefits of targeting and inducing apoptosis (killing) to remove a percentage of senescent cells using rapamycin, and neutraceuticals fisetin, and quercitin, with or without dasatinab.

 

11:50AM

Ben Best

NAD+ Restoration and Senolytic Therapy


Ben Best has subjected himself to two age reversal therapies: (1) senolytic therapy (therapy to eliminate senescent cells using dasatinib and quercetin) and (2) NAD+ infusions (to restore NAD+ to youthful levels). He has also attended several conferences dealing with these subjects as well as studied and written about them, the results of which he will provide in his presentation.

12:30PM

Break for Lunch 


1:30PM

Dr. Mike Perry

 A History of Cryonics in New York


From the earliest days of cryonics there were enthusiasts in the New York area. Their decision to form their own local organization led to the coining of “cryonics” for the company name: “Cryonics Society of New York”, while “cryonics” soon became known more generally for the practice of cryopreserving people for possible later revival. My talk will cover some highlights of early cryonics history in the New York area and culminate with showing a film made in 1968 for a cryonics conference in March that year.

2:00PM

Chana Phaedra

An Introduction to Brain Preservation Optimization

 

Vitrification has the advantage that it does not need different cryoprotectant protocols for different cell- and tissue types. Vitrification of the brain does presents two distinct challenges: low tolerance to ischemia and poor blood-brain barrier permeability of cryoprotectants. In this presentation I will review the history of brain cryopreservation, the status of brain cryopreservation research, and future directions.

 

2:40PM

Aschwin de Wolf

 Revival of "Straight Frozen" Patients


Freezing of the brain without cryoprotectant (a "straight freeze") is considered the worst cryopreservation scenario but there is a paucity of ultrastructural evidence how the straight frozen brain actually looks like. Aschwin de Wolf will review electron micrographs of the straight frozen brain (under a variety of conditions) and will discuss how "medical cryobots" will prepare the brain for molecular repair and infer the original non-frozen state from the damaged state.

 

 

3:20PM

Michael Benjamin

 Alcor Meta-Analysis

  

Several attempts have been made to create quantitative case outcome methodologies in cryonics. Advanced Neural Biosciences has embarked on a comprehensive meta-analysis of all Alcor patient cases, an endeavor whose goal is to develop, experimentally validate, and refine a quantitative cryopreservation evaluation methodology. Michael will be presenting some preliminary statistics gathered during Phase 1 of the study so far.

 

3:40PM

15 Minute Break

3:55PM

Dr. Ralf Spindler

Functional evaluation of brain preservation protocols

 
Currently, reversible vitrification of whole brains is limited by neurotoxicity of the very concentrated vitrification solutions involved. Here, an automated assay is described which has proven to quantify synaptic connections in live-cell neuronal networks by a high-content confocal imaging method. Since it is known that synaptodentritic damage, especially the decrease in number of synaptic connections, correlates with cognitive decline the assay could be used to evaluate brain preservation protocols.

 

4:35PM

Dr. Roman Bauer

Computational Biology Methods for Tissue Cryopreservation

 
In contrast to most other biomedical fields, tissue cryopreservation has remained relatively untouched by computational techniques. State-of the-art cryopreservation still predominantly relies on trial-and-error and large numbers of experiments for the determination of protocol parameters. Roman Bauer will review milestones in computational and mathematical work towards better cryopreservation protocols, and will discuss how he sees future automated cryopreservation technologies maximize post-thaw tissue quality.


 

5:15PM

Dr. Emil Kendziorra

Professionalization and Scaling of Medical Biostasis
 

With only a few thousand members world-wide, medical biostasis has stayed a very small field, albeit being around for decades. In Europe the topic has been even more niche. The EBF (European Biostasis Foundation) based in Switzerland, has recently set out to fundamentally change this situation with four main areas of activity - sign up / stand-by, storage, research and long-term asset management. Emil Kendziorra will present the core activities to professionalize medical biostasis and scale the field. 

 

5:55PM

Dr. Robin Hanson

 Hidden Motives Help Explain

Why Cryonics Isn’t Popular


 The usual pro-cryonics argument frames it as medicine, to be evaluated in terms of its technical ability to prolong life. However, though they are unaware of it, for most people medicine is more about showing that they care than about prolonging life. Robin Hanson reviews the evidence that many big areas of life are driven by hidden motives quite different from what people usually say, and then tries to apply this insight to help us understand why so few people actually choose cryonics.

6:35PM

Dinner and Socializing


7:45 PM

Closing Remarks


8:00 PM

Event Conclusion


TECHNOLOGY IS BEST WHEN IT BRINGS PEOPLE TOGETHER

MATT MULLENWEG

OUR SPONSORS

Thank you so much for your support.

referral link triangle icon
CONTACT THE ORGANIZER
Google   Outlook   iCal   Yahoo
Sorry, ticket sales have closed.